
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
High efficacy has no single definition, and a large toolbox means little when formularies limit access. The panel describes how patient preference, route of administration, and payer constraints shape real decisions.
Episodes in this series

"Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice" takes up the question of what clinicians mean by high efficacy and what actually reaches patients.
Dr. Nair asks each panelist how they define high efficacy. Dr. Freeman says no one debates that anti-CD20 agents, natalizumab, and alemtuzumab qualify. Classification of cladribine and S1P modulators varies, and in her view S1P modulators can be high efficacy in the right patients, although they are often considered medium-high efficacy in the United States.
She notes that no side-by-side trials exist. Studies used placebo or active comparators and enrolled different populations. She explains to patients that high efficacy describes the share of people who stay stable across a trial of thousands. It does not predict an individual response, and a person can respond fully to a low-efficacy drug.
Dr. Freeman adds that although more than 20 drugs are approved, payers and formularies narrow the real toolbox. A patient may want a subcutaneous option and be unable to get one, so she argues for access within classes to support shared decision-making.
Dr. Newsome describes a patient who chose ocrelizumab and then declined the subcutaneous option because of trauma from earlier injectable therapies. He says payer constraints vary by region. His team writes letters of medical necessity, calls medical directors, and uses free-drug programs. He notes that industry partners have been helpful in providing temporary supply. He advises less experienced clinicians to phone an MS specialist and co-treat, since most patients are treated outside MS centers.
Dr. Longbrake describes a young patient who refused infusions, injections, and daily pills. He accepted cladribine, taken 10 days a year for two years. Dr. Newsome adds that trial investigators voted on efficacy data to place cladribine among the early aggressive therapies, while S1P modulators landed in the traditional group after debate.
Up next, in "MS Treatment Guidelines and Payer Step Therapy: Finding Balance," the panel reviews what MS guidelines cover and how step therapy collides with the idea that time is brain.
Related to this article








